biotech · Lupus Nephritis · Primary or Secondary Progressive Multiple Sclerosis · KYTX
Kyverna Therapeutics
Kyverna Therapeutics clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 5980 Horton St, Suite 550, Emeryville, California 94608, US
- Founded
- 2018
- Employees
- 155
- Programs
- 14
- Drugs
- 31
- Patents
- 2
Kyverna Therapeutics projects
8 ClinicalTrials.gov programs sponsored by Kyverna Therapeutics.
Kyverna Therapeutics has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CCM-RNT-202402
Kyverna Therapeutics
ANCA-IgG-positive ANCA Associated Vasculitis
1 trial -
KYV-101
Kyverna Therapeutics
Multiple Sclerosis, Primary Progressive
1 trial -
KYV-101
Kyverna Therapeutics
Systemic Sclerosis
1 trial -
KYV-101 anti-CD19 CAR-T cell therapy
Kyverna Therapeutics
Lupus Nephritis
2 trials -
KYV101
Kyverna Therapeutics
Rheumatoid Arthritis
1 trial -
KYV101-003
Kyverna Therapeutics
Lupus Nephritis
1 trial -
KYV101-007
Kyverna Therapeutics
Primary or Secondary Progressive Multiple Sclerosis
1 trial -
Standard lymphodepletion regimen
Kyverna Therapeutics
Stiff-Person Syndrome
1 trial
Frequently asked questions
How many clinical projects does Kyverna Therapeutics have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.